Foghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Foghorn Therapeutics said its 50-50 Lilly collaboration on FHD-909 remains on track, with a decision on whether to proceed to expansion expected sometime over the summer of 2026. The company also highlighted progress on its CBP selective degrader for ER-positive breast cancer, including completed non-GLP tox studies and ongoing animal pharmacology work in combination with oral SERDs and CDK4/6 inhibitors. The update is largely developmental and guidance-focused, with no financial metrics disclosed.

Analysis

The market is likely underappreciating that this is a binary summer event with asymmetric implications for the entire FHTX setup. A positive collaboration expansion decision would de-risk the platform in a way that changes funding duration, partner validation, and the implied probability of success across the rest of the pipeline; a negative decision would not just hit the lead asset, it would also force a reset of the company’s “optionality” premium and likely pressure the stock well before any hard cash runway issue becomes visible.

Second-order, the key winner in a constructive outcome is not just FHTX but any small-cap epigenetic/oncology platform names that trade on partnering credibility rather than near-term commercialization. The loser set includes adjacent preclinical oncology stories whose valuations depend on the market assuming that large pharma will continue paying up for platform access; if Lilly pauses or narrows the relationship, the read-through could compress partner optionality multiples across the SMID biotech space for several months.

The contrarian angle is that the market may be too focused on the summer decision as a pure go/no-go when the more important variable is the quality of the expansion economics and what they imply about Lilly’s willingness to fund broader clinical optionality. If expansion is announced with a measured scope, the stock could initially dip despite being fundamentally positive, creating a better entry than a headline-chasing move. Conversely, if management cannot show clear pharmacology translation in the CBP program, investors should expect the selloff to be sharper than consensus models assume because the market is still paying for platform breadth rather than one asset.

Key Decisions for Investors

• Go long FHTX into the summer catalyst only on pullbacks or after confirmation of improving pharmacology signals; target a 2-3x upside on a positive expansion decision versus ~30-40% downside if the collaboration is not expanded.
• For event-driven accounts, buy near-dated FHTX call spreads into the catalyst window rather than outright stock; this caps premium bleed while preserving convexity into a binary announcement.
• Pair trade: long FHTX / short a basket of preclinical oncology platform names with weaker partner support, for a 3-6 month horizon; the trade monetizes any re-rating to validated-platform scarcity while hedging sector beta.
• If the stock rallies hard on rumor or incremental updates before the formal decision, trim 25-50% of exposure; the risk/reward usually worsens materially once the market prices in most of the positive outcome.
• If collaboration expansion is announced but scope is narrower than expected, consider buying post-gap weakness only if liquidity remains intact; that setup can offer a better entry on a still-validated platform with a reset valuation.